This symposium will explore the challenges and innovative approaches in treating RAI-refractory advanced thyroid cancers. Professor Makoto Tahara will discuss strategies for optimizing multikinase inhibitor therapy in RAI-refractory DTC while preserving patients' quality of life. Professor Mingzhao Xing will highlight recent advancements in targeted therapy for advanced thyroid cancers. Finally, Professor Dong-Jun Lim will share his insights on the role of highly selective tyrosine kinase inhibitors for thyroid cancer. This symposium will offer a valuable platform to share the latest research and clinical perspectives aimed at improving the management of advanced thyroid cancers.

Iodine is an essential micronutrient for thyroid hormone synthesis; however, excessive iodine exposure/intake can lead to thyroid diseases. This session will discuss thyroidal risk associated with excessive iodine based on recent research findings. Prof. Angela M. Leung will lecture on the thyroid dysfunction risk caused by iodine excess, Prof. Hye In Kim will present on the relationship between excessive iodine intake and thyroid cancer, and Prof. Sun Wook Cho will discuss the effects of iodine excess on the thyroid during pregnancy.

This session highlights the latest research trends that uncover the characteristics of various thyroid cancer types through multiomics approaches. Prof. Yoo Hyung Kim will present proteogenomic analyses of follicular cell-derived thyroid neoplasms, Prof. Yu Wang will discuss proteo-epigenomic profiling of medullary thyroid cancer, and Prof. Yea Eun Kang will explore metabolomic analyses of advanced thyroid cancers. Together, these lectures provide a comprehensive and multidimensional understanding of the mechanisms underlying thyroid cancer development and progression.